Peramivir

From Wikipedia, the free encyclopedia

Peramivir
Systematic (IUPAC) name
(1S,2S,3S,4R)-3-[(1S)-1-Acetamido-2-ethyl-butyl]

-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane -1-carboxylic acid

Identifiers
CAS number 229614-55-5
ATC code  ?
PubChem 151164
Chemical data
Formula C15H28N4O4 
Mol. mass 328.407 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.[1]

The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability.[2] BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.[3] [4]

[edit] Sources